FDA approves Novo Nordisk's injection for obesity
December 23, 2014 at 17:14 PM EST
Dec 23 (Reuters) - The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans.
